UK Smooths Clinical Trial Pathway To Reassure Companies With Brexit Jitters
The UK is revising its clinical trial processes to align them with the new EU Clinical Trials Regulation so that companies can seek authorization just as easily in the UK as in other EU member states, irrespective of the situation after Brexit.
You may also be interested in...
Having gained enough experience with the combined ethics and regulatory review of clinical trial applications, the UK will make this its only route for evaluating new drug trial applications starting next year.
A new pre-assessment service for COVID-19 clinical trials that was established by the UK medicines regulator to cut down on review times is being extended to a limited number of other kinds of trials.
The UK insists there have been no major changes to the clinical trial environment since the country voted to leave the EU more than three years ago. It says the country continues to be an attractive location for clinical research.